HURA TuHURA Biosciences Inc.

$HURA TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

$HURA Intismeran autogene and IFx-2.0 differ not only in how patient-specific treatment is created, but in how tumor neoantigens are presented to the immune system. Intismeran is built around a computationally selected set of patient-specific tumor neoantigens. IFx-2.0 is designed to use the patient’s own tumor as the source of neoantigens, allowing antigen-presenting cells to process and present all neoantigens from the tumor itself potentially providing a more biologically efficient mechanism That may allow immune recognition to extend beyond a computer predicted set of selected neoantigens, with the potential for broader antigen recognition through more efficient and comprehensive epitope spreading. Whether that biological distinction translates into a clinical advantage remains to be established in ongoing trials. $MRNA $MRK

$HURA The FDA’s clearance allowing us to proceed with a Phase 1b study of TBS-2025 is an important moment for TuHURA, and its significance reaches beyond our own pipeline. It opens the way for the first human clinical study of a VISTA-inhibiting antibody in a molecularly defined subset of acute myeloid leukemia (AML). In AML marked by an NPM1 mutation, the mutation drives VISTA expression on leukemic blasts, contributing to immune escape. TBS-2025 is designed to block this negative checkpoint and will be evaluated in patients who did not respond to, or relapsed after, menin inhibitor therapy. Our mission is to address the reasons cancer immunotherapies fail to work or stop working. Bringing this approach into clinical evaluation extends that mission to patients with molecularly defined subsets of several blood-related cancers, beginning with a patient population that has no approved or effective treatment options.

$HURA TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

$HURA when the company posts more than investors or traders on here, you know something ain’t right.

$HURA Our mission moves forward through science, with each clinical step designed to answer a specific question. With FDA clearance now in place, TBS-2025 can advance into a Phase 1b study in patients with relapsed or refractory acute myeloid leukemia (AML) marked by an NPM1 mutation who did not respond to, or relapsed after, menin inhibitor therapy. The study will initially evaluate safety and potential efficacy across multiple monotherapy dose levels. Following review of the safety data with the FDA, it is expected to progress to dose optimization to determine a safe and biologically effective dose.

$HURA the intismeran autogene news didn’t give a bump to Hura or others in similar immunotherapy space. Why? Intismeran autogene prevents recurrence after the tumor is removed. Perhaps the market thinks unresectable tumors will overwhelm the immune system.

$HURA took a $650,000 draw on its revolving credit facility, adding to the $50 million loan for general corporate purposes.